Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

IFNL4 Genotypes Predict Clearance of RNA Viruses in Rwandan Children With Upper Respiratory Tract Infections.

Rugwizangoga B, Andersson ME, Kabayiza JC, Nilsson MS, Ármannsdóttir B, Aurelius J, Nilsson S, Hellstrand K, Lindh M, Martner A.

Front Cell Infect Microbiol. 2019 Oct 4;9:340. doi: 10.3389/fcimb.2019.00340. eCollection 2019.

2.

Persistence rate of cervical human papillomavirus infections and abnormal cytology in Rwanda.

Mukanyangezi MF, Rugwizangoga B, Manzi O, Rulisa S, Hellstrand K, Tobin G, Martner A, Bienvenu E, Giglio D.

HIV Med. 2019 Aug;20(7):485-495. doi: 10.1111/hiv.12782.

PMID:
31318136
3.

Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.

Nilsson MS, Hallner A, Brune M, Nilsson S, Thorén FB, Martner A, Hellstrand K.

Hum Vaccin Immunother. 2019 Jul 24:1-3. doi: 10.1080/21645515.2019.1636598. [Epub ahead of print]

PMID:
31242079
4.

Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.

Aurelius J, Möllgård L, Kiffin R, Ewald Sander F, Nilsson S, Thorén FB, Hellstrand K, Martner A.

Leuk Lymphoma. 2019 Nov;60(11):2771-2778. doi: 10.1080/10428194.2019.1599110. Epub 2019 Apr 17.

PMID:
30991860
5.

The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.

Hallner A, Bernson E, Hussein BA, Ewald Sander F, Brune M, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Blood. 2019 Mar 28;133(13):1479-1488. doi: 10.1182/blood-2018-09-874990. Epub 2019 Jan 15.

6.

NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.

Aydin E, Hallner A, Grauers Wiktorin H, Staffas A, Hellstrand K, Martner A.

Oncogene. 2019 Feb;38(9):1534-1543. doi: 10.1038/s41388-018-0528-1. Epub 2018 Oct 15.

7.

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.

Grauers Wiktorin H, Nilsson MS, Kiffin R, Sander FE, Lenox B, Rydström A, Hellstrand K, Martner A.

Cancer Immunol Immunother. 2019 Feb;68(2):163-174. doi: 10.1007/s00262-018-2253-6. Epub 2018 Oct 12.

8.

NOX2 in autoimmunity, tumor growth and metastasis.

Martner A, Aydin E, Hellstrand K.

J Pathol. 2019 Feb;247(2):151-154. doi: 10.1002/path.5175. Epub 2018 Nov 29.

9.

Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus.

Nyström K, Wanrooij PH, Waldenström J, Adamek L, Brunet S, Said J, Nilsson S, Wind-Rotolo M, Hellstrand K, Norder H, Tang KW, Lagging M.

J Virol. 2018 Sep 12;92(19). pii: e01087-18. doi: 10.1128/JVI.01087-18. Print 2018 Oct 1.

10.

Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.

Bernson E, Hallner A, Sander FE, Nicklasson M, Nilsson MS, Christenson K, Aydin E, Liljeqvist JÅ, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Cancer Immunol Res. 2018 Sep;6(9):1110-1119. doi: 10.1158/2326-6066.CIR-17-0711. Epub 2018 Jul 6.

11.

Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.

Kiffin R, Grauers Wiktorin H, Nilsson MS, Aurelius J, Aydin E, Lenox B, Nilsson JA, Ståhlberg A, Thorén FB, Hellstrand K, Martner A.

Front Oncol. 2018 Jun 18;8:218. doi: 10.3389/fonc.2018.00218. eCollection 2018.

12.

Role of NOX2-Derived Reactive Oxygen Species in NK Cell-Mediated Control of Murine Melanoma Metastasis.

Aydin E, Johansson J, Nazir FH, Hellstrand K, Martner A.

Cancer Immunol Res. 2017 Sep;5(9):804-811. doi: 10.1158/2326-6066.CIR-16-0382. Epub 2017 Jul 31.

13.

Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.

Sander FE, Nilsson M, Rydström A, Aurelius J, Riise RE, Movitz C, Bernson E, Kiffin R, Ståhlberg A, Brune M, Foà R, Hellstrand K, Thorén FB, Martner A.

Cancer Immunol Immunother. 2017 Nov;66(11):1473-1484. doi: 10.1007/s00262-017-2040-9. Epub 2017 Jul 18.

14.

Role of NOX2 for leukaemic expansion in a murine model of BCR-ABL1+ leukaemia.

Grauers Wiktorin H, Nilsson T, Aydin E, Hellstrand K, Palmqvist L, Martner A.

Br J Haematol. 2018 Jul;182(2):290-294. doi: 10.1111/bjh.14772. Epub 2017 May 23. No abstract available.

PMID:
28542840
15.

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.

Bernson E, Hallner A, Sander FE, Wilsson O, Werlenius O, Rydström A, Kiffin R, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Leukemia. 2017 Dec;31(12):2552-2559. doi: 10.1038/leu.2017.151. Epub 2017 May 22.

16.

NOX2-dependent immunosuppression in chronic myelomonocytic leukemia.

Aurelius J, Hallner A, Werlenius O, Riise R, Möllgård L, Brune M, Hansson M, Martner A, Thorén FB, Hellstrand K.

J Leukoc Biol. 2017 Aug;102(2):459-466. doi: 10.1189/jlb.5VMA1116-454R. Epub 2017 Mar 14.

PMID:
28292946
17.

Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.

Rydström A, Hallner A, Aurelius J, Sander FE, Bernson E, Kiffin R, Thoren FB, Hellstrand K, Martner A.

J Leukoc Biol. 2017 Aug;102(2):467-474. doi: 10.1189/jlb.5VMA1116-455R. Epub 2017 Feb 24.

PMID:
28235771
18.

Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.

Werlenius O, Aurelius J, Hallner A, Akhiani AA, Simpanen M, Martner A, Andersson PO, Hellstrand K, Thorén FB.

Oncotarget. 2016 May 31;7(22):32046-53. doi: 10.18632/oncotarget.8769.

19.

Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Martner A, Rydström A, Riise RE, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB.

Oncoimmunology. 2015 May 5;5(1):e1041701. doi: 10.1080/2162402X.2015.1041701. eCollection 2016.

20.

Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.

Sander FE, Rydström A, Bernson E, Kiffin R, Riise R, Aurelius J, Anderson H, Brune M, Foà R, Hellstrand K, Thorén FB, Martner A.

Oncotarget. 2016 Feb 16;7(7):7586-96. doi: 10.18632/oncotarget.7210.

21.

NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.

Martner A, Rydström A, Riise RE, Aurelius J, Brune M, Foà R, Hellstrand K, Thorén FB.

Oncotarget. 2015 Dec 15;6(40):42569-74. doi: 10.18632/oncotarget.5559.

22.

Low Back and Leg Pain With Refusal to Ambulate in a 6-Year-Old Male.

Hellstrand K, Hoppa E.

Clin Pediatr (Phila). 2016 Nov;55(13):1260-1262. Epub 2015 Nov 4. No abstract available.

PMID:
26538588
23.

TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses.

Riise RE, Bernson E, Aurelius J, Martner A, Pesce S, Della Chiesa M, Marcenaro E, Bylund J, Hellstrand K, Moretta L, Moretta A, Thorén FB.

J Immunol. 2015 Aug 1;195(3):1121-8. doi: 10.4049/jimmunol.1500709. Epub 2015 Jun 17.

24.

Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase.

Martner A, Wiktorin HG, Lenox B, Ewald Sander F, Aydin E, Aurelius J, Thorén FB, Ståhlberg A, Hermodsson S, Hellstrand K.

J Immunol. 2015 May 15;194(10):5014-21. doi: 10.4049/jimmunol.1402991. Epub 2015 Apr 13.

25.

Reply: To PMID 24976330.

Chicaiza H, Hellstrand K, Lerer T, Smith S, Sylvester F.

J Pediatr. 2015 Mar;166(3):781-2. doi: 10.1016/j.jpeds.2014.11.050. Epub 2015 Jan 9. No abstract available.

PMID:
25578995
26.

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 favors sustained lymphocyte recovery in acute myeloid leukemia.

Hallner A, Aurelius J, Thorén FB, Sander FE, Brune M, Hellstrand K, Martner A.

Eur J Haematol. 2015 Mar;94(3):279-80. doi: 10.1111/ejh.12454. Epub 2014 Nov 21. No abstract available. Erratum in: Eur J Haematol. 2019 Jan;102(1):99.

PMID:
25256820
27.

Potassium hydroxide: an alternative reagent to perform the modified apt test.

Chicaiza H, Hellstrand K, Lerer T, Smith S, Sylvester F.

J Pediatr. 2014 Sep;165(3):628-30. doi: 10.1016/j.jpeds.2014.05.027. Epub 2014 Jun 26.

PMID:
24976330
28.

Absence of cytomegalovirus in high-coverage DNA sequencing of human glioblastoma multiforme.

Tang KW, Hellstrand K, Larsson E.

Int J Cancer. 2015 Feb 15;136(4):977-81. doi: 10.1002/ijc.29042. Epub 2014 Jul 7.

29.

Reply: To PMID 24519039.

Lagging M, Rembeck K, Waldenström J, Nilsson S, Nyström K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, Färkkilä M, Langeland N, Buhl MR, Mørch K, Christensen PB, Hellstrand K.

Hepatology. 2014 Dec;60(6):2130-1. doi: 10.1002/hep.27108. Epub 2014 Sep 24. No abstract available.

PMID:
24591101
30.

Role of the ERK pathway for oxidant-induced parthanatos in human lymphocytes.

Akhiani AA, Werlenius O, Aurelius J, Movitz C, Martner A, Hellstrand K, Thorén FB.

PLoS One. 2014 Feb 21;9(2):e89646. doi: 10.1371/journal.pone.0089646. eCollection 2014.

31.

Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.

Rembeck K, Waldenström J, Hellstrand K, Nilsson S, Nyström K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, Färkkilä M, Langeland N, Buhl MR, Mørch K, Christensen PB, Lagging M.

Hepatology. 2014 Jun;59(6):2131-9. doi: 10.1002/hep.27009. Epub 2014 Apr 25.

PMID:
24519039
32.

Valganciclovir in patients with glioblastoma.

Hellstrand K, Martner A, Bergström T.

N Engl J Med. 2013 Nov 21;369(21):2066. doi: 10.1056/NEJMc1312413. No abstract available.

PMID:
24256397
33.

Immunotherapeutic strategies for relapse control in acute myeloid leukemia.

Martner A, Thorén FB, Aurelius J, Hellstrand K.

Blood Rev. 2013 Sep;27(5):209-16. doi: 10.1016/j.blre.2013.06.006. Epub 2013 Jul 18. Review.

PMID:
23871358
34.

Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.

Lagging M, Rembeck K, Rauning Buhl M, Christensen P, Dalgard O, Färkkilä M, Hellstrand K, Langeland N, Lindh M, Westin J, Norkrans G.

Scand J Gastroenterol. 2013 Jul;48(7):839-47. doi: 10.3109/00365521.2013.793389.

PMID:
23795661
35.

Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.

Lindh M, Arnholm B, Björkman P, Hellstrand K, Lagging M, Nilsson S, Wahlberg T, Wallmark E, Weiland O, Wejstål R, Westin J, Widell A, Norkrans G.

J Viral Hepat. 2013 Apr;20(4):e82-9. doi: 10.1111/jvh.12014. Epub 2012 Oct 16.

PMID:
23490394
36.

Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.

Söderholm J, Waldenström J, Askarieh G, Pilli M, Bochud PY, Negro F, Pawlotsky JM, Zeuzem S, Ferrari C, Norkrans G, Wejstål R, Westin J, Neumann AU, Haagmans BL, Lindh M, Missale G, Hellstrand K, Lagging M.

PLoS One. 2013;8(2):e56991. doi: 10.1371/journal.pone.0056991. Epub 2013 Feb 20.

37.

Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes.

Aurelius J, Martner A, Riise RE, Romero AI, Palmqvist L, Brune M, Hellstrand K, Thorén FB.

J Leukoc Biol. 2013 Jan;93(1):155-60. doi: 10.1189/jlb.0512257. Epub 2012 Oct 16.

PMID:
23072905
38.

PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection.

Rembeck K, Maglio C, Lagging M, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Norkrans G, Hellstrand K, Lindh M, Pirazzi C, Burza MA, Romeo S, Westin J; NORDynamIC group.

BMC Med Genet. 2012 Sep 14;13:82. doi: 10.1186/1471-2350-13-82.

39.

Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.

Aurelius J, Martner A, Brune M, Palmqvist L, Hansson M, Hellstrand K, Thoren FB.

Haematologica. 2012 Dec;97(12):1904-8. doi: 10.3324/haematol.2012.066399. Epub 2012 Jun 11.

40.

Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.

Alsiö Å, Rembeck K, Askarieh G, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Nasic S, Westin J, Hellstrand K, Norkrans G, Lagging M.

PLoS One. 2012;7(5):e37521. doi: 10.1371/journal.pone.0037521. Epub 2012 May 24.

41.

Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis.

Aurelius J, Thorén FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, Hellstrand K, Martner A.

Blood. 2012 Jun 14;119(24):5832-7. doi: 10.1182/blood-2011-11-391722. Epub 2012 May 1.

42.

The recurrent Guillain-Barré syndrome: a long-term population-based study.

Mossberg N, Nordin M, Movitz C, Nilsson S, Hellstrand K, Bergström T, Andersson B, Andersen O.

Acta Neurol Scand. 2012 Sep;126(3):154-61. doi: 10.1111/j.1600-0404.2012.01667.x. Epub 2012 Apr 17.

PMID:
22507178
43.

Association between interleukin-28B-related genetic variants and liver histopathology differs between hepatitis C virus genotypes.

Rembeck K, Westin J, Lindh M, Hellstrand K, Norkrans G, Laging M; NORDynamIC study group.

Hepatology. 2012 Jul;56(1):394. doi: 10.1002/hep.25598. Epub 2012 Jun 6. No abstract available.

PMID:
22270967
44.

Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3.

Rembeck K, Alsiö A, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Westin J, Lindh M, Hellstrand K, Norkrans G, Lagging M.

PLoS One. 2012;7(1):e29370. doi: 10.1371/journal.pone.0029370. Epub 2012 Jan 13.

45.

Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.

Alsiö A, Jannesson A, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Westin J, Hellstrand K, Norkrans G, Lagging M; NORDynamIC Study Group.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1631-5. doi: 10.1007/s10096-011-1486-5. Epub 2011 Nov 24.

PMID:
22113307
46.

Redox remodeling by dendritic cells protects antigen-specific T cells against oxidative stress.

Martner A, Aurelius J, Rydström A, Hellstrand K, Thorén FB.

J Immunol. 2011 Dec 15;187(12):6243-8. doi: 10.4049/jimmunol.1102138. Epub 2011 Nov 16.

47.

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, Norkrans G, Söderholm J, Wahlberg T, Wejstål R, Westin J, Hellstrand K.

J Viral Hepat. 2011 Jul;18(7):e325-31. doi: 10.1111/j.1365-2893.2010.01425.x. Epub 2011 Jan 13.

PMID:
21692944
48.

Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus.

Lindh M, Lagging M, Färkkilä M, Langeland N, Mørch K, Nilsson S, Norkrans G, Pedersen C, Buhl MR, Westin J, Hellstrand K.

J Infect Dis. 2011 Jun 15;203(12):1748-52. doi: 10.1093/infdis/jir193.

PMID:
21606533
49.

Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.

Buyse M, Michiels S, Squifflet P, Lucchesi KJ, Hellstrand K, Brune ML, Castaigne S, Rowe JM.

Haematologica. 2011 Aug;96(8):1106-12. doi: 10.3324/haematol.2010.039131. Epub 2011 May 5.

50.

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.

Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K; DITTO-HCV Study Group.

PLoS One. 2011 Feb 24;6(2):e17232. doi: 10.1371/journal.pone.0017232.

Supplemental Content

Loading ...
Support Center